Decades of market research shows that the best-performing stocks often have an 80 or higher RS Rating in the early stages of ...

Globus Medical (NYSE:GMED) has been analyzed by 5 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. Summarizing their recent assessments ...

Pennsylvania-based Globus Medical, Inc. company is primarily focused on products for knee and hip procedures, as well as robotic and imaging systems. However, its main business is providing a wide ...

RBC Capital analyst Shagun Singh Chadha maintained a Buy rating on Globus Medical (GMED – Research Report) on April 15 and set a price target ...

NuVasive infringed five patents from a spine surgeon, a jury determined, according to an April 22 report from Bloomberg Law. The jury ruled that screw assemblies from the Reline, Armada and VuePoint ...

The acquisition expands Globus Medical’s reach in the musculoskeletal market and the opportunity to add to its product portfolio. The deal was first announced in February, and Nevro was valued ...

Globus Medical GMED has outperformed the market over the past 10 years by 1.08% on an annualized basis producing an average annual return of 11.62%. Currently, Globus Medical has a market ...

It is hard to get excited after looking at Globus Medical's (NYSE:GMED) recent performance, when its stock has declined 17% over the past three months. It seems that the market might have completely ...